Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | C1R | P00736 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925152 | 0.80 | NPSR1 (0.47) | L3MBTL1TDP1ATMKMT2AMEN1 | |
| SCHEMBL2335117 | 0.76 | HTR2A (0.54) | L3MBTL1TDP1ATMKMT2AMEN1 | |
| SCHEMBL6678379 | 0.71 | L3MBTL1 (0.51) | L3MBTL1TDP1ATMKMT2AMEN1 | |
| SCHEMBL15916018 | 0.71 | L3MBTL1 (0.45) | L3MBTL1TDP1ATMKMT2AMEN1 | |
| SCHEMBL17075716 | 0.68 | MAPT (0.58) | L3MBTL1KMT2AMEN1MAPTPOLB | |
| SCHEMBL17075715 | 0.68 | MAPT (0.58) | L3MBTL1KMT2AMEN1MAPTPOLB | |
| SCHEMBL27140352 | 0.68 | LMNA (0.42) | KMT2AMEN1 | |
| SCHEMBL6632929 | 0.68 | L3MBTL1 (0.45) | L3MBTL1TDP1ATMKMT2AMEN1 | |
| SCHEMBL1925919 | 0.68 | L3MBTL1 (0.48) | L3MBTL1TDP1KMT2AMEN1MAPT | |
| SCHEMBL28750157 | 0.67 | CA1 (0.52) | L3MBTL1TDP1ATMKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-7776895-B2 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2042168-A1 | Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| EP-1425001-B1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-7439393-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| US-7361787-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| WO-2004039762-A1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | L3MBTL1 3675/4885TDP1 3374/4885ATM 3245/4885 |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | L3MBTL1 3904/4885TDP1 3709/4885ATM 3073/4885 |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | PNMT, CHRM3, HRH4 | L3MBTL1 741/4885TDP1 3712/4885ATM 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.